Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 1 to \<5 years on the day of inclusion~* History of received 1 dose of CD.JEVAX at 9-15 months prior to enrollment~* In good general health at the time of inclusion~* Provision of informed consent by the parent(s) or legal guardian(s)~Exclusion Criteria:~* Receipt of blood or blood products in the past 3 months~* Acute febrile illness on the day of vaccination (Body Temperature ≥ 38 ◦C)~* Previous receipt of 2 doses of any vaccine against JE virus~* Known hypersensitivity to any of the vaccine components~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* Planned receipt of any live attenuated vaccine within 4 weeks following the trial vaccination

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Imojev (Type: EXPERIMENTAL): Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

Based on this trial design, predict the completion outcome and termination type (if applicable).